English
简体中文
Total: £ 56.28
Published Date: 2025-11-12 | Pages: 125 | Tables: 117 | Medical Care
The global Biomarker of Disease market is projected to grow from US$ 32340 million in 2024 to US$ 89610 million by 2031, at a CAGR of 15.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Omics, proteomics, meta-bolomics technologies are used in biomarkers discovery and disease diagnosis. Biomarkers are used in risk assessment, molecular diagnostic, disease diagnosis, DNA fingerprinting and other molecular applications. Biomarkers enable pharmaceutical companies to analyze and discover novel drugs as demand for cost effective and efficient treatment dose is increasing. Biomarkers are used in drug validation and testing, sample preparation and assay development to eliminate complexity in discovery and development of novel drugs. Biomarkers of disease are used in identification of disease condition and also help in validation of clinical trials for novel drug.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Biomarker of Disease market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Aushon Biosystem
Bio-Rad Laboratories
Thermo Fisher Scientific Inc
Siemens AG
Eisai Co. Ltd
Roche Diagnostics Limited
Abbott Laboratories, Inc
Epistem Ltd
Ge Healthcare
Agilent Technologies Inc
Segment by Type
Sample Preparation
Assay Development
Biomarker Validation and Testing
Others
Segment by Application
Pharmaceutical Companies
Government & Private Research Institutes
Academic Institutes
Medical Device Manufacturing Companies
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Biomarker of Disease study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Biomarker of Disease: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biomarker of Disease Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Sample Preparation
1.2.3 Assay Development
1.2.4 Biomarker Validation and Testing
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Biomarker of Disease Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Companies
1.3.3 Government & Private Research Institutes
1.3.4 Academic Institutes
1.3.5 Medical Device Manufacturing Companies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biomarker of Disease Revenue Estimates and Forecasts 2020-2031
2.2 Global Biomarker of Disease Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Biomarker of Disease Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Biomarker of Disease Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Sample Preparation Market Size by Players
3.3.2 Assay Development Market Size by Players
3.3.3 Biomarker Validation and Testing Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Biomarker of Disease Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Biomarker of Disease Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Biomarker of Disease Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Biomarker of Disease Market Size by Type (2020-2031)
6.4 North America Biomarker of Disease Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Biomarker of Disease Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Biomarker of Disease Market Size by Type (2020-2031)
7.4 Europe Biomarker of Disease Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Biomarker of Disease Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Biomarker of Disease Market Size by Type (2020-2031)
8.4 Asia-Pacific Biomarker of Disease Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Biomarker of Disease Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Biomarker of Disease Market Size by Type (2020-2031)
9.4 Central and South America Biomarker of Disease Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Biomarker of Disease Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Biomarker of Disease Market Size by Type (2020-2031)
10.4 Middle East and Africa Biomarker of Disease Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Biomarker of Disease Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Aushon Biosystem
11.1.1 Aushon Biosystem Corporation Information
11.1.2 Aushon Biosystem Business Overview
11.1.3 Aushon Biosystem Biomarker of Disease Product Features and Attributes
11.1.4 Aushon Biosystem Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.1.5 Aushon Biosystem Biomarker of Disease Revenue by Product in 2024
11.1.6 Aushon Biosystem Biomarker of Disease Revenue by Application in 2024
11.1.7 Aushon Biosystem Biomarker of Disease Revenue by Geographic Area in 2024
11.1.8 Aushon Biosystem Biomarker of Disease SWOT Analysis
11.1.9 Aushon Biosystem Recent Developments
11.2 Bio-Rad Laboratories
11.2.1 Bio-Rad Laboratories Corporation Information
11.2.2 Bio-Rad Laboratories Business Overview
11.2.3 Bio-Rad Laboratories Biomarker of Disease Product Features and Attributes
11.2.4 Bio-Rad Laboratories Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.2.5 Bio-Rad Laboratories Biomarker of Disease Revenue by Product in 2024
11.2.6 Bio-Rad Laboratories Biomarker of Disease Revenue by Application in 2024
11.2.7 Bio-Rad Laboratories Biomarker of Disease Revenue by Geographic Area in 2024
11.2.8 Bio-Rad Laboratories Biomarker of Disease SWOT Analysis
11.2.9 Bio-Rad Laboratories Recent Developments
11.3 Thermo Fisher Scientific Inc
11.3.1 Thermo Fisher Scientific Inc Corporation Information
11.3.2 Thermo Fisher Scientific Inc Business Overview
11.3.3 Thermo Fisher Scientific Inc Biomarker of Disease Product Features and Attributes
11.3.4 Thermo Fisher Scientific Inc Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.3.5 Thermo Fisher Scientific Inc Biomarker of Disease Revenue by Product in 2024
11.3.6 Thermo Fisher Scientific Inc Biomarker of Disease Revenue by Application in 2024
11.3.7 Thermo Fisher Scientific Inc Biomarker of Disease Revenue by Geographic Area in 2024
11.3.8 Thermo Fisher Scientific Inc Biomarker of Disease SWOT Analysis
11.3.9 Thermo Fisher Scientific Inc Recent Developments
11.4 Siemens AG
11.4.1 Siemens AG Corporation Information
11.4.2 Siemens AG Business Overview
11.4.3 Siemens AG Biomarker of Disease Product Features and Attributes
11.4.4 Siemens AG Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.4.5 Siemens AG Biomarker of Disease Revenue by Product in 2024
11.4.6 Siemens AG Biomarker of Disease Revenue by Application in 2024
11.4.7 Siemens AG Biomarker of Disease Revenue by Geographic Area in 2024
11.4.8 Siemens AG Biomarker of Disease SWOT Analysis
11.4.9 Siemens AG Recent Developments
11.5 Eisai Co. Ltd
11.5.1 Eisai Co. Ltd Corporation Information
11.5.2 Eisai Co. Ltd Business Overview
11.5.3 Eisai Co. Ltd Biomarker of Disease Product Features and Attributes
11.5.4 Eisai Co. Ltd Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.5.5 Eisai Co. Ltd Biomarker of Disease Revenue by Product in 2024
11.5.6 Eisai Co. Ltd Biomarker of Disease Revenue by Application in 2024
11.5.7 Eisai Co. Ltd Biomarker of Disease Revenue by Geographic Area in 2024
11.5.8 Eisai Co. Ltd Biomarker of Disease SWOT Analysis
11.5.9 Eisai Co. Ltd Recent Developments
11.6 Roche Diagnostics Limited
11.6.1 Roche Diagnostics Limited Corporation Information
11.6.2 Roche Diagnostics Limited Business Overview
11.6.3 Roche Diagnostics Limited Biomarker of Disease Product Features and Attributes
11.6.4 Roche Diagnostics Limited Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.6.5 Roche Diagnostics Limited Recent Developments
11.7 Abbott Laboratories, Inc
11.7.1 Abbott Laboratories, Inc Corporation Information
11.7.2 Abbott Laboratories, Inc Business Overview
11.7.3 Abbott Laboratories, Inc Biomarker of Disease Product Features and Attributes
11.7.4 Abbott Laboratories, Inc Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.7.5 Abbott Laboratories, Inc Recent Developments
11.8 Epistem Ltd
11.8.1 Epistem Ltd Corporation Information
11.8.2 Epistem Ltd Business Overview
11.8.3 Epistem Ltd Biomarker of Disease Product Features and Attributes
11.8.4 Epistem Ltd Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.8.5 Epistem Ltd Recent Developments
11.9 Ge Healthcare
11.9.1 Ge Healthcare Corporation Information
11.9.2 Ge Healthcare Business Overview
11.9.3 Ge Healthcare Biomarker of Disease Product Features and Attributes
11.9.4 Ge Healthcare Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.9.5 Ge Healthcare Recent Developments
11.10 Agilent Technologies Inc
11.10.1 Agilent Technologies Inc Corporation Information
11.10.2 Agilent Technologies Inc Business Overview
11.10.3 Agilent Technologies Inc Biomarker of Disease Product Features and Attributes
11.10.4 Agilent Technologies Inc Biomarker of Disease Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Biomarker of DiseaseIndustry Chain Analysis
12.1 Biomarker of Disease Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Biomarker of Disease Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Biomarker of Disease Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Biomarker of Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Biomarker of Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Biomarker of Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Biomarker of Disease Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Biomarker of Disease Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Biomarker of Disease Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Biomarker of Disease Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Biomarker of Disease by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biomarker of Disease as of 2024)
Table 11. Global Biomarker of Disease Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Biomarker of Disease Companies Headquarters
Table 13. Global Biomarker of Disease Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Biomarker of Disease Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Biomarker of Disease Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Biomarker of Disease Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Biomarker of Disease Revenue by Application (2026-2031) & (US$ Million)
Table 21. Biomarker of Disease High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Biomarker of Disease Growth Accelerators and Market Barriers
Table 25. North America Biomarker of Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Biomarker of Disease Growth Accelerators and Market Barriers
Table 27. Europe Biomarker of Disease Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Biomarker of Disease Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Biomarker of Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Biomarker of Disease Investment Opportunities and Key Challenges
Table 31. Central and South America Biomarker of Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Biomarker of Disease Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Biomarker of Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Aushon Biosystem Corporation Information
Table 35. Aushon Biosystem Description and Major Businesses
Table 36. Aushon Biosystem Product Features and Attributes
Table 37. Aushon Biosystem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Aushon Biosystem Revenue Proportion by Product in 2024
Table 39. Aushon Biosystem Revenue Proportion by Application in 2024
Table 40. Aushon Biosystem Revenue Proportion by Geographic Area in 2024
Table 41. Aushon Biosystem Biomarker of Disease SWOT Analysis
Table 42. Aushon Biosystem Recent Developments
Table 43. Bio-Rad Laboratories Corporation Information
Table 44. Bio-Rad Laboratories Description and Major Businesses
Table 45. Bio-Rad Laboratories Product Features and Attributes
Table 46. Bio-Rad Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Bio-Rad Laboratories Revenue Proportion by Product in 2024
Table 48. Bio-Rad Laboratories Revenue Proportion by Application in 2024
Table 49. Bio-Rad Laboratories Revenue Proportion by Geographic Area in 2024
Table 50. Bio-Rad Laboratories Biomarker of Disease SWOT Analysis
Table 51. Bio-Rad Laboratories Recent Developments
Table 52. Thermo Fisher Scientific Inc Corporation Information
Table 53. Thermo Fisher Scientific Inc Description and Major Businesses
Table 54. Thermo Fisher Scientific Inc Product Features and Attributes
Table 55. Thermo Fisher Scientific Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Thermo Fisher Scientific Inc Revenue Proportion by Product in 2024
Table 57. Thermo Fisher Scientific Inc Revenue Proportion by Application in 2024
Table 58. Thermo Fisher Scientific Inc Revenue Proportion by Geographic Area in 2024
Table 59. Thermo Fisher Scientific Inc Biomarker of Disease SWOT Analysis
Table 60. Thermo Fisher Scientific Inc Recent Developments
Table 61. Siemens AG Corporation Information
Table 62. Siemens AG Description and Major Businesses
Table 63. Siemens AG Product Features and Attributes
Table 64. Siemens AG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Siemens AG Revenue Proportion by Product in 2024
Table 66. Siemens AG Revenue Proportion by Application in 2024
Table 67. Siemens AG Revenue Proportion by Geographic Area in 2024
Table 68. Siemens AG Biomarker of Disease SWOT Analysis
Table 69. Siemens AG Recent Developments
Table 70. Eisai Co. Ltd Corporation Information
Table 71. Eisai Co. Ltd Description and Major Businesses
Table 72. Eisai Co. Ltd Product Features and Attributes
Table 73. Eisai Co. Ltd Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Eisai Co. Ltd Revenue Proportion by Product in 2024
Table 75. Eisai Co. Ltd Revenue Proportion by Application in 2024
Table 76. Eisai Co. Ltd Revenue Proportion by Geographic Area in 2024
Table 77. Eisai Co. Ltd Biomarker of Disease SWOT Analysis
Table 78. Eisai Co. Ltd Recent Developments
Table 79. Roche Diagnostics Limited Corporation Information
Table 80. Roche Diagnostics Limited Description and Major Businesses
Table 81. Roche Diagnostics Limited Product Features and Attributes
Table 82. Roche Diagnostics Limited Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Roche Diagnostics Limited Recent Developments
Table 84. Abbott Laboratories, Inc Corporation Information
Table 85. Abbott Laboratories, Inc Description and Major Businesses
Table 86. Abbott Laboratories, Inc Product Features and Attributes
Table 87. Abbott Laboratories, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Abbott Laboratories, Inc Recent Developments
Table 89. Epistem Ltd Corporation Information
Table 90. Epistem Ltd Description and Major Businesses
Table 91. Epistem Ltd Product Features and Attributes
Table 92. Epistem Ltd Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Epistem Ltd Recent Developments
Table 94. Ge Healthcare Corporation Information
Table 95. Ge Healthcare Description and Major Businesses
Table 96. Ge Healthcare Product Features and Attributes
Table 97. Ge Healthcare Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Ge Healthcare Recent Developments
Table 99. Agilent Technologies Inc Corporation Information
Table 100. Agilent Technologies Inc Description and Major Businesses
Table 101. Agilent Technologies Inc Product Features and Attributes
Table 102. Agilent Technologies Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Agilent Technologies Inc Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Biomarker of Disease Product Picture
Figure 2. Global Biomarker of Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Sample Preparation Product Picture
Figure 4. Assay Development Product Picture
Figure 5. Biomarker Validation and Testing Product Picture
Figure 6. Others Product Picture
Figure 7. Global Biomarker of Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Pharmaceutical Companies
Figure 9. Government & Private Research Institutes
Figure 10. Academic Institutes
Figure 11. Medical Device Manufacturing Companies
Figure 12. Others
Figure 13. Biomarker of Disease Report Years Considered
Figure 14. Global Biomarker of Disease Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 16. Global Biomarker of Disease Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Biomarker of Disease Revenue Market Share by Region (2020-2031)
Figure 18. Global Biomarker of Disease Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Sample Preparation Revenue Market Share by Player in 2024
Figure 21. Assay Development Revenue Market Share by Player in 2024
Figure 22. Biomarker Validation and Testing Revenue Market Share by Player in 2024
Figure 23. Others Revenue Market Share by Player in 2024
Figure 24. Global Biomarker of Disease Revenue Market Share by Type (2020-2031)
Figure 25. Global Biomarker of Disease Revenue Market Share by Application (2020-2031)
Figure 26. North America Biomarker of Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Players Biomarker of Disease Revenue (US$ Million) in 2024
Figure 28. North America Biomarker of Disease Revenue (US$ Million) by Type (2020 - 2031)
Figure 29. North America Biomarker of Disease Revenue (US$ Million) by Application (2020-2031)
Figure 30. US Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 31. Canada Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 32. Mexico Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 33. Europe Biomarker of Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 34. Europe Top 5 Players Biomarker of Disease Revenue (US$ Million) in 2024
Figure 35. Europe Biomarker of Disease Revenue (US$ Million) by Type (2020-2031)
Figure 36. Europe Biomarker of Disease Revenue (US$ Million) by Application (2020-2031)
Figure 37. Germany Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 38. France Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 39. U.K. Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 40. Italy Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 41. Russia Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Biomarker of Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Top 8 Players Biomarker of Disease Revenue (US$ Million) in 2024
Figure 44. Asia-Pacific Biomarker of Disease Revenue (US$ Million) by Type (2020-2031)
Figure 45. Asia-Pacific Biomarker of Disease Revenue (US$ Million) by Application (2020-2031)
Figure 46. Indonesia Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 47. Japan Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 48. South Korea Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 49. Australia Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 50. India Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 51. Indonesia Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 52. Vietnam Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 53. Malaysia Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 54. Philippines Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 55. Singapore Biomarker of Disease Revenue (2020-2031) & (US$ Million)
Figure 56. Central and South America Biomarker of Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Central and South America Top 5 Players Biomarker of Disease Revenue (US$ Million) in 2024
Figure 58. Central and South America Biomarker of Disease Revenue (US$ Million) by Type (2020-2031)
Figure 59. Central and South America Biomarker of Disease Revenue (US$ Million) by Application (2020-2031)
Figure 60. Brazil Biomarker of Disease Revenue (2020-2025) & (US$ Million)
Figure 61. Argentina Biomarker of Disease Revenue (2020-2025) & (US$ Million)
Figure 62. Middle East and Africa Biomarker of Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Middle East and Africa Top 5 Players Biomarker of Disease Revenue (US$ Million) in 2024
Figure 64. South America Biomarker of Disease Revenue (US$ Million) by Type (2020-2031)
Figure 65. Middle East and Africa Biomarker of Disease Revenue (US$ Million) by Application (2020-2031)
Figure 66. GCC Countries Biomarker of Disease Revenue (2020-2025) & (US$ Million)
Figure 67. Israel Biomarker of Disease Revenue (2020-2025) & (US$ Million)
Figure 68. Egypt Biomarker of Disease Revenue (2020-2025) & (US$ Million)
Figure 69. South Africa Biomarker of Disease Revenue (2020-2025) & (US$ Million)
Figure 70. Biomarker of Disease Industry Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
